At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 843 enrolled
Drug / intervention
Aclidinium bromide +1 moredrug
Likely dose
Aclidinium bromide 200 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
In Brief
A Phase 3 clinical trial evaluating Aclidinium bromide and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 843 participants across 132 sites in 16 countries.
Detailed Summary
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAndorra, Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russia, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionMay 2008
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartJul 1, 2006
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.9 years ago
Interventions
Aclidinium bromidedrug
Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Placebodrug
Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks